JPMorgan Chase & Co. Boosts Travere Therapeutics (NASDAQ:TVTX) Price Target to $20.00

Travere Therapeutics (NASDAQ:TVTX) had its price objective boosted by JPMorgan Chase & Co. from $19.00 to $20.00 in a report released on Tuesday morning, Benzinga reports. They currently have an overweight rating on the stock.

A number of other analysts have also issued reports on the stock. Barclays boosted their target price on shares of Travere Therapeutics from $12.00 to $14.00 and gave the company an overweight rating in a research note on Friday, August 2nd. Canaccord Genuity Group boosted their target price on shares of Travere Therapeutics from $15.00 to $18.00 and gave the company a buy rating in a research note on Tuesday, May 7th. HC Wainwright boosted their target price on shares of Travere Therapeutics from $19.00 to $20.00 and gave the company a buy rating in a research note on Monday, August 5th. Piper Sandler upped their price objective on shares of Travere Therapeutics from $11.00 to $12.00 and gave the stock a neutral rating in a research note on Friday, August 2nd. Finally, Wedbush upped their price objective on shares of Travere Therapeutics from $13.00 to $16.00 and gave the stock an outperform rating in a research note on Friday, August 2nd. Five analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of Moderate Buy and a consensus price target of $15.67.

Travere Therapeutics Trading Up 2.9 %

TVTX stock opened at $8.78 on Tuesday. The company has a quick ratio of 2.99, a current ratio of 3.04 and a debt-to-equity ratio of 24.96. Travere Therapeutics has a twelve month low of $5.12 and a twelve month high of $15.39. The stock has a market capitalization of $671.58 million, a price-to-earnings ratio of -4.18 and a beta of 0.77. The firm’s fifty day simple moving average is $8.62 and its two-hundred day simple moving average is $7.74.

Hedge Funds Weigh In On Travere Therapeutics

Several hedge funds have recently modified their holdings of the stock. Forefront Analytics LLC increased its holdings in shares of Travere Therapeutics by 10.2% during the second quarter. Forefront Analytics LLC now owns 13,317 shares of the company’s stock valued at $109,000 after acquiring an additional 1,237 shares in the last quarter. Millennium Management LLC increased its holdings in Travere Therapeutics by 33.9% in the 2nd quarter. Millennium Management LLC now owns 2,949,335 shares of the company’s stock worth $24,244,000 after buying an additional 747,406 shares during the period. AQR Capital Management LLC increased its holdings in Travere Therapeutics by 55.7% in the 2nd quarter. AQR Capital Management LLC now owns 74,069 shares of the company’s stock worth $609,000 after buying an additional 26,485 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new position in Travere Therapeutics in the 2nd quarter worth approximately $291,000. Finally, Point72 DIFC Ltd acquired a new position in Travere Therapeutics in the 2nd quarter worth approximately $175,000.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.